Serum institute of technology

A Sydney-based biotechnology company NeuClone has inked a licensing agreement and joint development partnership with Serum Institute of India to manufacture and supply 10 biosimilar monoclonal antibody drugs globally. The products would treat diseases including cancer and autoimmune disorders. According to a recent company statement, the partnership would leverage NeuClone’s patented technology to generate protein drugs at much reduced cost from proprietary manufacturing cell lines and the immense biologics manufacturing capability of Serum Institute, the world’s largest vaccine producer. “After several years of technology development and building our team expertise, NeuClone is very pleased to launch this multi-product co-development programme with Serum Institute. “Our products will exemplify the competitive advantages of our NeuMAXTM technology platform for cell line development,” Noelle Sunstrom, NeuClone’s Founder and CEO, said. NeuClone has retained licence to the jointly developed biosimilars for the developed markets of USA, Europe, Canada, Australia, Taiwan, Japan and South Korea. For these markets NeuClone has been seeking partnerships with large Pharmaceutical and Generics companies who can best deliver these products via their existing market channels. For the rest of the world, including India, China, South East Asia, The Middle East, South America and Africa, Serum Institute has exclusive licence for marketing and sales. “We plan to extend the vision set by D...

Serum Institute of India (SII) CEO Adar Poonawalla said this week that the company planned to start its bridging study of the Covovax vaccine “soon”. It will also be stockpiling doses of the vaccine starting April. Newsletter | What is Covovax? This is SII’s version of NVX-CoV2373, the protein-based How does Covovax work? Like several other Covid-19 vaccines, Covovax targets the spike protein on the surface of the SARS-CoV-2 Modified spike genes are placed in a baculovirus, which is known to infect insects. This virus is then used to infect the moth cells, carrying the spike gene into the cell. The cells then create the spike proteins, which are harvested. After they are purified, a certain dosage of these spike proteins are used as the vaccine. Once a person is given a shot of this vaccine, their body is expected to recognise these copies of the spike proteins as a foreign substance and build immunity against them. When the real virus tries to infect the cell, the body is expected to be able to fight it off. What is the efficacy of Covovax? The vaccine recently showed an efficacy of 96.4% against mild to severe disease caused by the original strain of SARS-CoV-2 from ongoing late-stage global trials. It has also managed an efficacy of around 83.4% two weeks after the first dose — potentially promising finding at a time when vaccine makers might face hurdles in scaling up supplies. Against mutant variants of the virus, it showed an efficacy of around 86.3% (UK variant) and...

A technician waits to collect vials containing vaccine after they pass through a machine that checks for bottling and vaccine substance deficiencies. Viraj Nayar for NPR PUNE, India – Last spring, a father and son in India had a 5-minute chat over dinner that had the potential to change the course of the pandemic. Cyrus and Adar Poonawalla are the founder and CEO, respectively, of the Serum Institute of India. It's the world's largest vaccine-producing company in the world's largest vaccine-producing nation. Serum makes vaccines for measles, tetanus, diphtheria, hepatitis and many other diseases. It specializes in generic versions, exports to 170 countries – and Then came the coronavirus – and that fateful kitchen table conversation. Cyrus Poonawalla (left) and his son, Adar, are the founder and CEO, respectively, of the Serum Institute of India, the world's largest vaccine manufacturer. Despite its global scope, it remains a dad-and-son business. All it took to take a big pandemic gamble was a 5-minute dinner table conversation. Sanjit Das (photo of Cyrus Poonawalla) and Dhiraj Singh (photo of Adar Poonawalla)/Bloomberg via Getty Images hide caption toggle caption Sanjit Das (photo of Cyrus Poonawalla) and Dhiraj Singh (photo of Adar Poonawalla)/Bloomberg via Getty Images Adar Poonawalla, 40, If these vaccines did prove effective, Serum would already have hundreds of millions of doses stockpiled, to start shipping out. If they didn't, Serum would end up with useless vacci...

• Adani Enterp. 2433.95 ↓ -11.10 (-0.45%) • Adani Ports 738.80 ↑ 2.20 (0.30%) • Apollo Hospitals 4950.20 ↓ -17.10 (-0.34%) • Asian Paints 3199.75 ↓ -37.50 (-1.16%) • Axis Bank 950.85 ↑ 24.75 (2.67%) • B P C L 356.80 ↓ -3.25 (-0.90%) • Bajaj Auto 4710.05 ↑ 40.95 (0.88%) • Bajaj Finance 7043.20 ↑ 19.30 (0.27%) • Bajaj Finserv 1458.90 ↑ 1.65 (0.11%) • Bharti Airtel 834.50 ↓ -2.00 (-0.24%) • Britannia Inds. 4682.60 ↑ 28.45 (0.61%) • Cipla 974.80 ↑ 8.95 (0.93%) • Coal India 229.70 ↓ -1.20 (-0.52%) • Divi's Lab. 3462.30 ↓ -49.30 (-1.40%) • Dr Reddy's Labs 4603.55 ↓ -6.90 (-0.15%) • Eicher Motors 3673.25 ↓ -26.15 (-0.71%) • Grasim Inds 1734.50 ↑ 23.95 (1.40%) • H D F C 2644.80 ↓ -1.10 (-0.04%) • HCL Technologies 1138.30 ↑ 1.25 (0.11%) • HDFC Bank 1604.40 ↓ -2.10 (-0.13%) • HDFC Life Insur. 574.15 ↓ -2.25 (-0.39%) • Hero Motocorp 2870.60 ↓ -22.05 (-0.76%) • Hind. Unilever 2695.80 ↓ -20.90 (-0.77%) • Hindalco Inds. 419.70 ↓ -1.05 (-0.25%) • ICICI Bank 946.75 ↑ 8.60 (0.92%) • IndusInd Bank 1301.80 ↑ 13.60 (1.06%) • Infosys 1304.50 ↑ 5.50 (0.42%) • ITC 440.65 ↓ -2.75 (-0.62%) • JSW Steel 712.15 ↑ 5.55 (0.79%) • Kotak Mah. Bank 1924.90 ↓ -13.85 (-0.71%) • Larsen & Toubro 2268.30 ↑ 33.75 (1.51%) • M & M 1395.40 ↑ 54.00 (4.03%) • Maruti Suzuki 9582.10 ↑ 96.75 (1.02%) • Nestle India 21834.15 ↓ -212.30 (-0.96%) • NTPC 174.10 ↓ -0.45 (-0.26%) • O N G C 155.40 ↑ 0.70 (0.45%) • Power Grid Corpn 235.60 ↑ 1.00 (0.43%) • Reliance Industr 2477.25 ↑ 22.05 (0.90%) • SBI Life Insuran 1215.40 ↑ 12.9...